HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer and Stage IV Breast Cancer Clinical Trial Using entinostat, lapatinib ditosylate, trastuzumab and laboratory biomarker analysis

- The folks at National Cancer Institute (NCI) are studying the effects of entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis on HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer and Stage IV Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start January 2012.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed."

Locations

M D Anderson Cancer Center

Houston, Texas - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.